Nuvation Bio Inc. Business Combination, Separately Recognized Transactions, Net Gains and Losses
Nuvation Bio Inc. (NUVB) reported Business Combination, Separately Recognized Transactions, Net Gains and Losses of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Income Statement › Other Income
us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses · last filed 2023-03-15
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2022-12-31 was $0.00.
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2021-12-31 was $0.00.
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2021-09-30 was $62.00K.
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for the quarter ending 2021-06-30 was $133.00K.
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for fiscal 2022 was $0.00.
- Nuvation Bio Inc. business combination, separately recognized transactions, net gains and losses for fiscal 2021 was -$624.77M.
| Period end | Business Combination, Separately Recognized Transactions, Net Gains and Losses 3 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 3 month as first filed | Business Combination, Separately Recognized Transactions, Net Gains and Losses 6 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 6 month as first filed | Business Combination, Separately Recognized Transactions, Net Gains and Losses 9 month | Business Combination, Separately Recognized Transactions, Net Gains and Losses 9 month as first filed | Business Combination, Separately Recognized Transactions, Net Gains and Losses 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 | |||||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $62.00K derived: sum of 2 quarters · filed 2023-03-15 | $195.00K derived: sum of 3 quarters · filed 2023-03-15 | -$624.77M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $195.00K derived: sum of 2 quarters · filed 2022-11-03 | -$624.77M 10-Q · filed 2022-11-03 | $624.77M 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$624.83M 10-Q · filed 2022-08-04 | $624.83M 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | -$624.96M 10-Q · filed 2022-05-09 | $624.96M 10-Q · filed 2021-05-17 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |